To mark JJDC’s 45th anniversary, GCV spoke to Asish Xavier and Renee Ryan, both vice-presidents for venture investments, who focus on biotech and medical devices respectively, and Stacy Feld, vice-president of consumer venture investments and external innovation.

JJDC has more experience than any healthcare corporate venturing division, with a legacy that stretches back to 1973. Its prominence has continued into 2018, with approximately 40 new and follow-on investments and more than $450m supplied globally, making it the leading healthcare CVC unit for disclosed investments over the past 12 months, according to deals database PitchBook.

The unit relies on a 13-person investment team spread throughout locations in New Jersey and Tel Aviv and the four Johnson & Johnson…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?